Journal article
The prevention and management of Crohn's disease postoperative recurrence: results from the Y-ECCO/ClinCom 2019 Survey
Gabriele Dragoni, Nik Ding, Krisztina B Gecse, John C Mansfield, Uri Kopylov, Laurent Beaugerie, Peter Bossuyt, Shaji Sebastian, Monica Milla, Siro Bagnoli, Nuha A Yassin, Dominik Bettenworth, Johan Burisch, Charlotte Hedin, Javier P Gisbert, Marc Ferrante
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2020
Abstract
BACKGROUND: Prevention and management of postoperative recurrence (POR) is a controversial field in Crohn's disease. The aim of this survey was to report common practice in real-life settings. METHODS: An 11-question survey was distributed among gastroenterologists attending the 14th European Crohn's and Colitis Organisation (ECCO) congress. RESULTS: Postoperative endoscopy to assess recurrence was routinely performed within 12 months by 87% of respondents. Forty-six percent of clinicians reported to maintain endoscopic assessment in routine follow-up even after first negative colonoscopy. Most respondents (60%) considered starting postoperative immunoprophylaxis in naïve patients if one or ..
View full abstractGrants
Funding Acknowledgements
G.D. has received travel grants from AbbVie, Pfizer, and Takeda. K.B.G. has received consultancy fees or speaker's honoraria from Amgen, AbbVie, Biogen, Boehringer Ingelheim, Ferring, Hospira, Immunic Therapeutics, Janssen, MSD, Pfizer, Sandoz, Samsung Bioepis, Takeda, Tigenix, and Tillotts. U.K. has received research support from Janssen, Takeda, and Medtronic. Speaker and advisory fees -Abbvie, Takeda, Jansen. Medtronic, and MSD. L.B. has received consulting fees from Janssen, Pfizer, and Allergan, lecture fees from Abbvie, Janssen, MSD, Ferring Pharmaceuticals, Mayoly-Spendler, Takeda and Tillotts, and research support from Abbott, Ferring Pharmaceuticals, Hospira-Pfizer, Janssen, MSD, Takeda and Tillotts. P.B. has received educational grants from AbbVie, Mundipharma, Pfizer, Janssen, Mylan; speaker fees from AbbVie, Takeda, Pfizer, Janssen; and advisory board fees from Hospira, Janssen, MSD, Mundipharma, Roche, Pfizer, Sandoz, Takeda, Abbvie, Mylan, and Pentax. S.S. holds research grants from Takeda, AbbVie, Warner Chilcott, Ferring, MSD, Biohit and Celgene, serves on the advisory boards of Takeda, AbbVie, Merck, Ferring, Pharmacocosmos, Warner Chilcott, Janssen, Falk Pharma, Biohit, TriGenix, Cellgene and Tillots Pharma, and has received speaker fees from Abbvie, Janssen, Merck, Warner Chilcott and Falk Pharma. S.B. has received speaker's honoraria from Takeda. D.B. is on the advisory board or consultant for Amgen, AbbVie, Dr. Falk Foundation, Ferring, MSD, Pfizer, Pharmacosmos, Roche, Takeda, Tillotts Pharma and Vifor. C.H. has received speaker fees from Takeda, Ferring, Abbvie and Janssen, consultancy fees from Pfizer. J.P.G. has served as a speaker, a consultant and advisory member for or has received research funding from MSD, Abbvie, Hospira, Pfizer, Kern Pharma, Biogen, Takeda, Janssen, Roche, Sandoz, Celgene, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, Vifor Pharma. M.F. received financial support for research from Amgen, Biogen, Pfizer, Takeda, and Janssen; lecture fees from Ferring, Boehringer-Ingelheim, Chiesi, Merck Sharpe & Dohme, Tillotts, Janssen Biologics, Abbvie, Takeda, Mitsubishi Tanabe, Zeria; consultancy fees from Abbvie, Boehringer-Ingelheim, Ferring, Janssen Biologics, Merck Sharpe & Dohme, and Takeda.